Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,495.00 77.47 0.54%
TOPIX 1,169.76 3.17 0.27%
HANG SENG 22,760.24 64.23 0.28%

CombiMatrix Announces it Has Regained Compliance With Nasdaq Minimum Stockholders' Equity Requirement



CombiMatrix Announces it Has Regained Compliance With Nasdaq Minimum
Stockholders' Equity Requirement

IRVINE, Calif., Aug. 21, 2013 (GLOBE NEWSWIRE) -- CombiMatrix Corporation
(Nasdaq:CBMX), a molecular diagnostics company specializing in DNA-based
testing services for developmental disorders and cancer diagnostics, today
announced that in a letter dated August 20, 2013, from the Director of Listing
Qualifications of The Nasdaq Stock Market LLC, the Company was informed that
it has regained compliance with Listing Rule 5550(b)(1) (the Rule), which
requires a minimum of $2.5 million stockholders' equity for The Nasdaq Capital
Market.

The letter from Nasdaq said that based on the Company's Form 10-Q for the
period ended June 30, 2013, which evidenced stockholders' equity of $5.7
million, the Nasdaq Staff has determined that CombiMatrix complies with the
Rule and "the matter is now closed."

There can be no assurance, however, that the Company will be able to maintain
compliance long-term with Nasdaq requirements for continued listing.

About CombiMatrix Corporation

CombiMatrix Corporation provides valuable molecular diagnostic solutions and
comprehensive clinical support for the highest quality of care – specializing
in miscarriage analysis, prenatal and pediatric healthcare. CombiMatrix offers
comprehensive testing services for the detection of genetic abnormalities at
the DNA level, beyond what can be identified through traditional
methodologies. The Company performs genetic testing utilizing advanced
technologies, including microarray, FISH, PCR and G-Band chromosome analyses.
Additional information about CombiMatrix is available at www.combimatrix.com
or by calling 1-800-710-0624.

CONTACT: Company Contact:
         Mark McDonough
         President & CEO, CombiMatrix Corporation
         Tel (949) 753-0624
        
         Media Contact:
         Len Hall
         VP, Media Relations
         Allen & Caron
         Tel (949) 474-4300
         len@allencaron.com
        
         Investor Relations Contact:
         John Baldissera
         BPC Financial Marketing
         Tel (800) 368-1217

CombiMatrix Corporation
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement